Elaheh Ahmadi, Ali Pourmotabbed, Nilofar Aghaz, Seyed Ershad Nedaei, Mojgan Veisi, Zahra Salimi, Fatemeh Zarei, Cyrus Jalili, Farshad Moradpour, Motahareh Zeinivand
Background and purpose: Depression is a growing public health concern worldwide, characterized by cognitive impairment and structural abnormalities of the hippocampus. Current antidepressant treatment sometimes causes the late onset of results and the much faster occurrence of side effects. For this reason, the interest in new treatment strategies including exercise and natural products such as curcumin has increased to treat depression. The present study investigated the role of curcumin and exercise in improving depressive-like behavior and hippocampal damage induced by mild unpredictable chronic stress in male rats.
Experimental approach: This study analyzed the effects of curcumin (100 mg/kg/day, P.O for 14 days) and exercise (treadmill running, 45 min/day for 14 days) on immobility behavior (forced swimming test), locomotor activity (open field test), anhedonia (sucrose preference test) and cell survival (Nissl staining) of the hippocampal CA3 region in chronically stressed depression rats.
Findings/Results: In the current study, curcumin treatment combined with exercise effectively improved immobility behavior, locomotor activity, and increased hippocampal cell survival resulted in preventing the development of hippocampus dysfunction and depressive-like behaviors.
Conclusion and implications: This study demonstrated a new prospect for treating depression. The current findings give researchers the confidence to continue the investigations on the effects of curcumin accompanied with exercise as a novel therapy for the treatment of depression.
Physiol Behav. 2005 Mar 31;84(4):571-7
[PMID:
15811392]
Behav Brain Res. 2012 May 16;231(1):130-7
[PMID:
22465167]
Front Cell Neurosci. 2019 Jan 07;12:516
[PMID:
30666189]
Front Pharmacol. 2022 Nov 23;13:1008249
[PMID:
36506556]
Saudi J Biol Sci. 2022 Aug;29(8):103311
[PMID:
35762011]
J Psychiatr Res. 2013 Mar;47(3):299-306
[PMID:
23201228]
Physiol Behav. 2008 Sep 3;95(1-2):125-9
[PMID:
18571208]
Behav Brain Res. 2021 Feb 5;399:113002
[PMID:
33161033]
J Affect Disord. 2017 Jan 01;207:188-196
[PMID:
27723543]
Int J Pharm. 2021 Jun 15;603:120670
[PMID:
33964337]
Am J Psychiatry. 2018 Jan 1;175(1):28-36
[PMID:
28969440]
Eur J Pharmacol. 2008 Jan 6;578(1):43-50
[PMID:
17942093]
Behav Brain Res. 2014 Dec 15;275:191-200
[PMID:
25192638]
Brain Res Bull. 2018 Oct;143:181-193
[PMID:
30236533]
Front Behav Neurosci. 2020 Jan 08;13:272
[PMID:
31969809]
Int J Neuropsychopharmacol. 2020 Feb 1;23(2):76-87
[PMID:
31774497]
Curr Issues Mol Biol. 2023 Aug 04;45(8):6449-6465
[PMID:
37623226]
PLoS Med. 2013 Nov;10(11):e1001547
[PMID:
24223526]
J Affect Disord. 2018 Feb;227:126-135
[PMID:
29055260]
Mol Psychiatry. 2020 Mar;25(3):530-543
[PMID:
31801966]
Brain Behav Immun Health. 2021 May 27;15:100278
[PMID:
34589778]
Neuropsychopharmacology. 2018 Dec;43(13):2627-2635
[PMID:
29487370]
Brain Sci. 2022 Sep 24;12(10):
[PMID:
36291221]
Physiol Behav. 2020 Dec 1;227:113140
[PMID:
32828030]
Science. 2012 Oct 5;338(6103):72-5
[PMID:
23042885]
Drug Des Devel Ther. 2016 Sep 20;10:3029-3042
[PMID:
27703331]
Dement Geriatr Cogn Disord. 2015;40(5-6):311-39
[PMID:
26360014]
Artif Cells Nanomed Biotechnol. 2017 Feb;45(1):98-107
[PMID:
26747522]
J Obstet Gynaecol Res. 2021 Oct;47(10):3669-3676
[PMID:
34254406]
Crit Rev Food Sci Nutr. 2020;60(15):2643-2653
[PMID:
31423805]
Rehabil Res Pract. 2014;2014:627376
[PMID:
24800081]
Nat Protoc. 2012 May 03;7(6):1009-14
[PMID:
22555240]
PLoS One. 2019 Apr 15;14(4):e0215554
[PMID:
30986274]
Front Neuroendocrinol. 2018 Apr;49:114-123
[PMID:
29428548]
Front Cell Neurosci. 2020 Feb 21;14:25
[PMID:
32153365]
J Therm Biol. 2020 Jan;87:102458
[PMID:
31999599]
Clin Psychopharmacol Neurosci. 2020 Aug 31;18(3):341-351
[PMID:
32702213]
Carcinogenesis. 2007 Aug;28(8):1765-73
[PMID:
17522064]
Nutrients. 2017 Dec 28;10(1):
[PMID:
29283372]
J Neurosci Methods. 2023 Jul 15;395:109910
[PMID:
37394102]
Am J Psychiatry. 2006 Nov;163(11):1905-17
[PMID:
17074942]
Neurosci Biobehav Rev. 2018 Jan;84:1-11
[PMID:
29128579]
Eur J Pharmacol. 2023 Jan 5;938:175435
[PMID:
36463946]
Transl Psychiatry. 2021 Nov 28;11(1):603
[PMID:
34840332]
Heliyon. 2023 Jul 17;9(7):e18380
[PMID:
37519641]
Basic Clin Pharmacol Toxicol. 2020 Oct;127(4):243-253
[PMID:
32544307]